Centaur Pharmaceuticals Launches Generic Chronic Heart Failure Drug in US

The company secured 180-day exclusivity time period for its generic ivabradine hydrochloride

By launching a generic version of the chronic heart failure medicine, Centaur Pharmaceuticals Pvt. Ltd. has made a significant advancement in the American pharmaceutical market. Ivabradine hydrochloride is an FDA-approved drug that reduces the risk of heart failure in adult patients with stable, symptomatic chronic heart failure and for the treatment of stable, symptomatic heart failure caused by dilated cardiomyopathy in young children.

Highlighting the potential of this newly launched drug to strengthen the company’s standing in the U.S. chronic heart failure drug sector, the company’s Chairman and Managing Director, S.D. Sawant, expressed his optimism and confidence in this launch. He also stated that the company’s long-term strategy is to expand its presence globally and collaborate with industry leaders to drive growth. With a strong track record across the pharmaceutical value chain, from research and production to active pharmaceutical ingredients, Centaur Pharmaceuticals is one of the leading fully integrated pharmaceutical firms in India. Furthermore, the firm has a strong global presence, with 42% of its profit obtained from international exports to more than 96 countries. The company secured 180-day exclusivity time period for its generic ivabradine hydrochloride along with its marketing partner, Ingenus Pharmaceuticals.

The drug, in 5 mg and 7.5 mg tablet formulations, is available in the U.S. market. With this new launch, the company stays committed to its aim of offering affordable treatment options to patients across the world.